To use all functions of this page, please activate cookies in your browser.
my.chemeurope.com
With an accout for my.chemeurope.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
PhosloPhosLo® consists of the mineral calcium acetate. It is an orally given phosphate binder used in patients with End Stage Renal Disease (ESRD). When taken with meals it combines with dietary phosphate in order for the body to eliminate it without absorbing it. High phosphate levels lead to hyperphosphatemia which can result in a myriad of problems. Serum calcium levels should be checked frequently when on PhosLo®. Patients with hypercalcemia should not take PhosLo® and no other calcium supplements should be taken with PhosLo®. Side effects can include hypercalcemia, nausea, and itching. Additional recommended knowledgeHistoryPhosLo® was owned by Nabi Biopharmaceuticals until late 2006 when it and its related assests was sold to the US subsidiary of Fresenius Medical Care. As of November 14, 2006 Nabi stopped distributing PhosLo®. References1. http://www.fresenius.se/internet/fag/com/faginpub.nsf/Content/P-Info+2007+01+23 2. http://www.nabi.com/products/product.php?id=1 3. http://bioflorida.com/node/196 |
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Phoslo". A list of authors is available in Wikipedia. |